$ALGN · ALIGN TECHNOLOGY INC
Align Technology reported Q3 FY2026 results with revenue of $1.015B, up 1.9% YoY but down 3.9% sequentially. Clear Aligner volume grew 6.6% YoY to 690,635 cases, while Imaging Systems revenue fell 7.6% YoY to $175.5M. GAAP EPS was $1.90 and non-GAAP EPS was $2.80. The company guided Q4 revenue to $1.00B-$1.02B and FY2026 revenue to $4.11B-$4.13B, with management citing persistent softness in discretionary healthcare spending.
- Q3 revenue of $1.015B fell 3.9% sequentially from Q2's $1.056B, with Imaging Systems down 7.6% YoY.
- Q4 revenue guidance of $1.00B-$1.02B implies another sequential decline; FY2026 guide of $4.11B-$4.13B.
- GAAP diluted EPS of $1.90 vs $0.78 YoY; non-GAAP EPS of $2.80 vs $2.61 YoY — modest 7.3% growth.
- Clear Aligner volume hit 690,635 cases, up 6.6% YoY but down 0.2% sequentially — first sequential volume decline in recent quarters.
- CFO cited 'softer environment for discretionary healthcare spending' persisting through Q3 and shaping cautious Q4 outlook.
Extended-hours trading shows ALGN at $148.65, down 3.24% vs the regular-session close of $153.62. The sequential revenue decline and cautious Q4 guide are driving the selloff despite YoY EPS growth.
Align's first sequential Clear Aligner volume decline in recent quarters, combined with below-consensus Q4 guidance, challenges the growth narrative for a $10.9B med-tech leader.
Align's cautious outlook mirrors broader dental/orthodontic sector weakness. The NXT Technology 3D-printing platform and Invisalign Sports Guard pilot represent product diversification bets amid a sluggish core market.
CFO explicitly flagged persistent softness in discretionary healthcare spending and capital equipment investment, with Q4 guidance assuming no consumer recovery. Imaging Systems revenue continues to contract, down 7.6% YoY and 5.3% sequentially.